Items where authors include "Jackson, GH"

Article

Panopoulou, A, Cairns, DA orcid.org/0000-0002-2338-0179, Holroyd, AE et al. (13 more authors) (2022) Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients. Blood. ISSN 0006-4971

Cook, G orcid.org/0000-0001-7196-7364, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (1 more author) (2022) Defining FiTNEss for treatment for multiple myeloma. The Lancet Healthy Longevity, 3 (11). e729-e730. ISSN 2666-7568

Agbuduwe, C, Iqbal, G, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (12 more authors) (2022) Clinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials. Blood Advances, 6 (17). pp. 5113-5123. ISSN 2473-9529

de Tute, RM, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2022) Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 40 (25). pp. 2889-2900. ISSN 0732-183X

Caro, J, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 22 (4). E279-E284. ISSN 2152-2650

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British Journal of Haematology, 192 (5). bjh.16945. pp. 853-868. ISSN 0007-1048

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Jackson, GH, Davies, FE, Pawlyn, C et al. (20 more authors) (2020) Lenalidomide Before And After ASCT For Transplant-Eligible Patients Of All Ages In The Randomized, Phase III, Myeloma XI Trial. Haematologica. haematol.2020.247130. ISSN 0390-6078

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Pratt, G et al. (13 more authors) (2020) Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy. British Journal of Haematology. ISSN 0007-1048

Boyle, EM, Ashby, C, Tytarenko, R et al. (25 more authors) (2020) BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 26 (10). pp. 2422-2432. ISSN 1078-0432

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 6 (12). e616-e629. ISSN 2352-3026

Jones, JR, Weinhold, N, Ashby, C et al. (19 more authors) (2019) Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 104 (7). pp. 1440-1450. ISSN 0390-6078

Cook, G orcid.org/0000-0003-0223-3652, Royle, K-L, Pawlyn, C et al. (10 more authors) (2019) A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematology, 6 (3). pp. 154-166. ISSN 2352-3026

Jackson, GH, Davies, FE, Pawlyn, C et al. (19 more authors) (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (1). pp. 57-73. ISSN 1470-2045

Went, M, Sud, A, Speedy, H et al. (52 more authors) (2018) Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal, 9. ARTN 1. ISSN 2044-5385

Yadav, P, Cockwell, P, Cook, M et al. (10 more authors) (2018) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrology, 19 (1). 178. ISSN 1471-2369

Royle, K-L, Gregory, WM orcid.org/0000-0003-2641-8416, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (8 more authors) (2018) Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. British Journal of Haematology, 182 (6). pp. 816-829. ISSN 0007-1048

Campbell, JP, Heaney, JLJ, Pandya, S et al. (10 more authors) (2017) Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematology. ISSN 2352-3026

Campbell, JP, Heaney, JLJ, Pandya, S et al. (9 more authors) (2017) Active multiple myeloma suppresses and typically eliminates coexisting MGUS. British Journal of Cancer, 117 (6). pp. 835-839. ISSN 0007-0920

Shah, V, Sherborne, AL, Walker, BA et al. (19 more authors) (2017) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1,905 trial patients. Leukemia, 32. pp. 102-110. ISSN 0887-6924

Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385

Pawlyn, C, Kaiser, MF, Heuck, C et al. (20 more authors) (2016) The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clinical Cancer Research, 22 (23). pp. 5783-5794. ISSN 1078-0432

Mitchell, JS, Li, N, Weinhold, N et al. (55 more authors) (2016) Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nature Communications, 7. 12050.

Johnson, DC, Weinhold, N, Mitchell, J et al. (18 more authors) (2016) Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia, 30 (4). pp. 883-888. ISSN 0887-6924

de Tute, RM, Rawstron, AC, Gregory, WM et al. (9 more authors) (2016) Minimal Residual Disease Following Autologous Stem Cell Transplant In Myeloma: Impact On Outcome Is Independent Of Induction Regimen. Haematologica, 101 (2). e69-e71. ISSN 0390-6078

Johnson, DC, Weinhold, N, Mitchell, JS et al. (19 more authors) (2016) Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nature Communications, 7. 10290.

Walker, BA, Boyle, EM, Wardell, CP et al. (24 more authors) (2015) Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 33 (33). pp. 3911-3920. ISSN 0732-183X

Mitchell, JS, Johnson, DC, Litchfield, K et al. (8 more authors) (2015) Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Scientific Reports, 5. 12473. ISSN 2045-2322

Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2015) APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 6. ARTN 6997.

Proceedings Paper

Shah, V, Johnson, DC, Sherborne, AL et al. (18 more authors) (2018) Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, California, USA. American Society of Hematology , p. 2000.

Jackson, GH, Davies, FE, Pawlyn, C et al. (18 more authors) (2018) A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San DIego, California, USA. American Society of Hematology , p. 302.